Emerging Markets Regulatory Tracker: Australia, India (Vol. 4 No. 14)
This article was originally published in PharmAsia News
Australia’s Therapeutic Goods Administration warns hip, knee and should implant firms to seek reclassification by June 30, while India’s health ministry wants urgent oversight of stem cells.
You may also be interested in...
India’s health ministry has laid out basic steps towards an overhaul of drug regulation at the local level, identifying a number of areas of concern.
China has released the results of back on proposed standards for the accreditation of clinical trial committees, investigators and sites.
China has finalized revised rules for the classification of medical devices, which will come into effect from the start of next year.